Corporate Members
The Pennsylvania Society of Oncology and Hematology expresses its gratitude to our corporate members. Contirbutions from the following companies help us in fulfilling our mission.
To learn more about becoming a Corporate Member, please click here.
To learn more about becoming a Corporate Member, please click here.
10k Members
AbbVie
About Us:
AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Oncology Research & Treatment
AbbVie advances cancer research and treatment to elevate the standard of care for blood cancer patients, and in the future other cancers like solid tumors.
Representatives:
Judith Aronson [email protected]
Kathy Wagner – [email protected]
Jim Lajeunesse [email protected]
Jay Raczkowski [email protected]
Steve Quarin [email protected]
Website: http://www.abbvie.com
Social Media:
https://www.linkedin.com/company/abbvie
https://twitter.com/abbvie
https://www.facebook.com/AbbVieGlobal/#
https://www.instagram.com/abbvie
https://www.youtube.com/user/AbbVie
https://www.tiktok.com/@abbvie
AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Oncology Research & Treatment
AbbVie advances cancer research and treatment to elevate the standard of care for blood cancer patients, and in the future other cancers like solid tumors.
Representatives:
Judith Aronson [email protected]
Kathy Wagner – [email protected]
Jim Lajeunesse [email protected]
Jay Raczkowski [email protected]
Steve Quarin [email protected]
Website: http://www.abbvie.com
Social Media:
https://www.linkedin.com/company/abbvie
https://twitter.com/abbvie
https://www.facebook.com/AbbVieGlobal/#
https://www.instagram.com/abbvie
https://www.youtube.com/user/AbbVie
https://www.tiktok.com/@abbvie
AstraZeneca
About Us:
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. AstraZeneca Oncology has a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Representative Contact:
Jessica Klouser: [email protected]
Tamara Lenzi: [email protected]
Social Media Links:
Website: https://www.astrazeneca.com/our-therapy-areas/oncology.html#!
Twitter: @AstraZenecaUS
Facebook: AstraZeneca US Community Connections
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. AstraZeneca Oncology has a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Representative Contact:
Jessica Klouser: [email protected]
Tamara Lenzi: [email protected]
Social Media Links:
Website: https://www.astrazeneca.com/our-therapy-areas/oncology.html#!
Twitter: @AstraZenecaUS
Facebook: AstraZeneca US Community Connections
Bayer
About Us:
At Bayer, we are committed to improving patients' lives. Continuing a 150-year legacy leading the world in life sciences innovation, Bayer reaffirms our commitment to improving patients’ lives every day. We will continue working to develop therapies and deliver the first-in-class support and education programs that help today’s patients — and tomorrow’s.
Representative Contacts Juan Gonsalves- [email protected]
Sarah Blasser-sarah.blasser@bayer.com
Maryanne [email protected]
Social Media Links:
Website: https://www.bayer.com
LinkedIn: https://www.linkedin.com/company/bayer
Facebook: https://www.facebook.com/Bayer/
Twitter: https://x.com/bayerus
Instagram: https://www.instagram.com/bayerofficial/
You Tube: https://www.youtube.com/c/bayerglobal
At Bayer, we are committed to improving patients' lives. Continuing a 150-year legacy leading the world in life sciences innovation, Bayer reaffirms our commitment to improving patients’ lives every day. We will continue working to develop therapies and deliver the first-in-class support and education programs that help today’s patients — and tomorrow’s.
Representative Contacts Juan Gonsalves- [email protected]
Sarah Blasser-sarah.blasser@bayer.com
Maryanne [email protected]
Social Media Links:
Website: https://www.bayer.com
LinkedIn: https://www.linkedin.com/company/bayer
Facebook: https://www.facebook.com/Bayer/
Twitter: https://x.com/bayerus
Instagram: https://www.instagram.com/bayerofficial/
You Tube: https://www.youtube.com/c/bayerglobal
BeOne Medicines
About Us
(formerly BeiGene - Press Release)
We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.
Website:
https://beonemedicines.us/about/beone/
myBeOne Support® Patient Support Program
Representative
Brent Coleman
[email protected]
Bristol Myers Squibb
About us: Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Website:
https://www.bms.com/
BMS Access Support patient assistance: https://www.bmsaccesssupport.bmscustomerconnect.com/#
Representative:
Rich Boyle
Associate Director – US State Societies and Congresses
US Hematology & Cell Therapy Portfolio Marketing and Channel Strategy
Mobile (570) 241-2441
[email protected]
Website:
https://www.bms.com/
BMS Access Support patient assistance: https://www.bmsaccesssupport.bmscustomerconnect.com/#
Representative:
Rich Boyle
Associate Director – US State Societies and Congresses
US Hematology & Cell Therapy Portfolio Marketing and Channel Strategy
Mobile (570) 241-2441
[email protected]
Daiichi Sankyo
About Us
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.
Website:
www.dsi.com
www.DSCancerEnterprise.com
Representatives:
Darren Geissler
Associate Director, Oncology Account Managment
Mobile: (717) 265-4783
[email protected]
Social Media:Twitter: @DaiichiSankyoUS
LinkedIn: https://www.linkedin.com/company/daiichi-sankyo
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.
Website:
www.dsi.com
www.DSCancerEnterprise.com
Representatives:
Darren Geissler
Associate Director, Oncology Account Managment
Mobile: (717) 265-4783
[email protected]
Social Media:Twitter: @DaiichiSankyoUS
LinkedIn: https://www.linkedin.com/company/daiichi-sankyo
Exelixis
About Us
Our story is one of dedication to patients and to scientific excellence. Over the course of the past three decades, we’ve evolved into a multi-platform cancer company. Today, we are innovating with both small molecules and biotherapeutics to build a diversified portfolio of cancer treatments that give patients hope for the future.
Website:
https://www.exelixis.com/
Representative:
Bob Zeigler
Senior Oncology Account Manager
610-517-2500 (mobile)
[email protected]
Our story is one of dedication to patients and to scientific excellence. Over the course of the past three decades, we’ve evolved into a multi-platform cancer company. Today, we are innovating with both small molecules and biotherapeutics to build a diversified portfolio of cancer treatments that give patients hope for the future.
Website:
https://www.exelixis.com/
Representative:
Bob Zeigler
Senior Oncology Account Manager
610-517-2500 (mobile)
[email protected]
GSK
About Us
At GSK Oncology our ambition is to help increase overall quality of life, maximize survival and change the course of disease.
Website:
http://www.gsks.com
Representatives:
Michelle Kodluk, Oncology Account Manager/Hematology, Philadelphia N.
Robin Beerhalter, Oncology Account Manager/Hematology, Philadelphia S.
Maria Calderaro, Oncology Account Manager, Philadelphia N.
Karl Bonsell, Oncology Account Manager/Hematology, Central PA
Gretchen Spitzer, Oncology Account Manager, Central PA
At GSK Oncology our ambition is to help increase overall quality of life, maximize survival and change the course of disease.
Website:
http://www.gsks.com
Representatives:
Michelle Kodluk, Oncology Account Manager/Hematology, Philadelphia N.
Robin Beerhalter, Oncology Account Manager/Hematology, Philadelphia S.
Maria Calderaro, Oncology Account Manager, Philadelphia N.
Karl Bonsell, Oncology Account Manager/Hematology, Central PA
Gretchen Spitzer, Oncology Account Manager, Central PA
Jazz Pharma
About Us
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are a leader in sleep disorders and epilepsy; further developing in movement disorders and PTSD; and focused on hematologic malignancies and solid tumors. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are a leader in sleep disorders and epilepsy; further developing in movement disorders and PTSD; and focused on hematologic malignancies and solid tumors. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.
Janssen
About Us:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Website: Learn more at https://www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine.
Social Media: Follow us at @JanssenUS and @JNJInnovMed
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Website: Learn more at https://www.jnj.com/ or at www.janssen.com/johnson-johnson-innovative-medicine.
Social Media: Follow us at @JanssenUS and @JNJInnovMed
Merck
About Us:Our focus on cancer research and treatments: We work with urgency to pursue breakthrough science to not only prolong lives, but protect them, too. Because people with cancer deserve more — more ways to treat their cancer, more quality in their lives and more time.
We’re committed to advancing cancer research with one of the largest development programs in the industry across more than 30 tumor types.
Website: https://www.merck.com/research-and-products/oncology/
Representative Contact:
Mark Montello
[email protected]
Social Media Links:
Facebook: https://www.facebook.com/Merckinvents
Twitter: https://twitter.com/Merck
LinkedIn: https://www.linkedin.com/company/Merck
Instagram: https://www.instagram.com/Merck
YouTube: https://youtube.com/user/Merck
We’re committed to advancing cancer research with one of the largest development programs in the industry across more than 30 tumor types.
Website: https://www.merck.com/research-and-products/oncology/
Representative Contact:
Mark Montello
[email protected]
Social Media Links:
Facebook: https://www.facebook.com/Merckinvents
Twitter: https://twitter.com/Merck
LinkedIn: https://www.linkedin.com/company/Merck
Instagram: https://www.instagram.com/Merck
YouTube: https://youtube.com/user/Merck
Pfizer Oncology
Representatives:
Geraldine Olson, CPC
Oncology Field Reimbursement Manager - OH/PA/WV
332-244-2360 (work) | 859-307-8816 (cell)
[email protected]
Geraldine Olson, CPC
Oncology Field Reimbursement Manager - OH/PA/WV
332-244-2360 (work) | 859-307-8816 (cell)
[email protected]
PharmaEssentia
About Us: PharmaEssentia Corporation (TWSE: 6446), headquartered in Taipei, Taiwan, with U.S. subsidiaries in Burlington and Bedford, MA, is a rapidly growing and fully integrated biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives
and renowned scientists from U.S. biotechnology and pharmaceutical companies, the company has expanded its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung.
For more information, visit our website or find us on LinkedIn and X.
Website: https://www.pharmaessentia.com/
Representative Contact:
Carmine Lenzi
[email protected]
Social Media Links:
LinkedIn PharmaEssentia
X- PharmaEssentia
and renowned scientists from U.S. biotechnology and pharmaceutical companies, the company has expanded its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung.
For more information, visit our website or find us on LinkedIn and X.
Website: https://www.pharmaessentia.com/
Representative Contact:
Carmine Lenzi
[email protected]
Social Media Links:
LinkedIn PharmaEssentia
X- PharmaEssentia
Regeneron
About Us:
Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.
Website: www.regeneron.com
Representative Contacts:
Paul Scharf - Key Account Leader, [email protected]
Melissa Taylor – Reimbursement Business Manager, [email protected]
Selena Kent - Senior Oncology Account Specialist, [email protected]
John Honus – Oncology Account Specialist, [email protected]
Josette Gephart – Oncology Account Specialist, [email protected]
Jacqueline Matthews – Oncology Account Specialist, [email protected]
Brandy Kurrell – Oncology Account Specialist, [email protected]
Reimbursement Link: https://www.libtayohcp.com/libtayo-surround
Social Media Links:
Facebook: https://www.facebook.com/Regeneron/
Twitter: https://twitter.com/Regeneron?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
LinkedIn: https://www.linkedin.com/company/regeneron-pharmaceuticals
Instagram: https://www.instagram.com/regeneron/?hl=en
Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.
Website: www.regeneron.com
Representative Contacts:
Paul Scharf - Key Account Leader, [email protected]
Melissa Taylor – Reimbursement Business Manager, [email protected]
Selena Kent - Senior Oncology Account Specialist, [email protected]
John Honus – Oncology Account Specialist, [email protected]
Josette Gephart – Oncology Account Specialist, [email protected]
Jacqueline Matthews – Oncology Account Specialist, [email protected]
Brandy Kurrell – Oncology Account Specialist, [email protected]
Reimbursement Link: https://www.libtayohcp.com/libtayo-surround
Social Media Links:
Facebook: https://www.facebook.com/Regeneron/
Twitter: https://twitter.com/Regeneron?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
LinkedIn: https://www.linkedin.com/company/regeneron-pharmaceuticals
Instagram: https://www.instagram.com/regeneron/?hl=en
5k Members
Amgen
About Us:
At Amgen Oncology, our mission to serve patients drives all that we do. That's why we're relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform lives of people with cancer. For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.
Website:
www.amgenoncology.com/
Representatives:
Grace DeMartini
[email protected]
Social Media:
Twitter: twitter.com/amgenoncology
At Amgen Oncology, our mission to serve patients drives all that we do. That's why we're relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform lives of people with cancer. For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.
Website:
www.amgenoncology.com/
Representatives:
Grace DeMartini
[email protected]
Social Media:
Twitter: twitter.com/amgenoncology
AVEO Oncology
About Us
AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name.
Website:
https://www.aveooncology.com/
Representatives:
Michael Mcdonald
Oncology Account Manager
215-205-9773
[email protected]
Kristine Dunbar
Regional Director
908-208-1411
[email protected]
Social Media:
AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name.
Website:
https://www.aveooncology.com/
Representatives:
Michael Mcdonald
Oncology Account Manager
215-205-9773
[email protected]
Kristine Dunbar
Regional Director
908-208-1411
[email protected]
Social Media:
- LinkedIn: https://www.linkedin.com/company/aveo-oncology/
- facebook: https://www.facebook.com/AVEOOncology/
- X: https://x.com/aveooncology
Eli Lilly and Company
About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn.
For questions on the corporate boilerplate, please contact [email protected].
Website:
www.lilly.com
Representatives:
Kevin Coyne
Sr.Executive Account Manager, Regional Oncology
Lilly Value and Access
570-406-1548 (mobile)
[email protected]
Jennifer Mercado
Executive Business Director, Philadelphia Oncology District
609.667.8828 (office) | 609.975.2468 (mobile)
[email protected]
Social Media:
follow us on Facebook, Instagram, Twitter and LinkedIn
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn.
For questions on the corporate boilerplate, please contact [email protected].
Website:
www.lilly.com
Representatives:
Kevin Coyne
Sr.Executive Account Manager, Regional Oncology
Lilly Value and Access
570-406-1548 (mobile)
[email protected]
Jennifer Mercado
Executive Business Director, Philadelphia Oncology District
609.667.8828 (office) | 609.975.2468 (mobile)
[email protected]
Social Media:
follow us on Facebook, Instagram, Twitter and LinkedIn
EMD Serono
Website:
https://www.emdserono.com/us-en/expertise/oncology.html
Contacts:
[email protected]
[email protected]
[email protected]
Patient Assistance Programs:
Bavencio - Home (coverone.com)
Tepmetko - Home (oncnavigationcenter.com)
https://www.emdserono.com/us-en/expertise/oncology.html
Contacts:
[email protected]
[email protected]
[email protected]
Patient Assistance Programs:
Bavencio - Home (coverone.com)
Tepmetko - Home (oncnavigationcenter.com)
Kyowa Kirin
About Us
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we apply cutting-edge science and expertise in antibody research and engineering to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four global regions – Japan, Asia Pacific, North America and EMEA/International – we are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity, and a drive to advance innovations that have a profound impact on patients. You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com.
Website:
www.kyowakirin.com
Representative:
Nicole Lesterick, Oncology Account Manager, Kyowa Kirin, Inc., 135 US-202, Bedminster, NJ 07921
Social Media
LinkedIn: Kyowa Kirin, Inc.- U.S.
Twitter: @KyowaKirin_US
YouTube: Kyowa Kirin North
America
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we apply cutting-edge science and expertise in antibody research and engineering to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four global regions – Japan, Asia Pacific, North America and EMEA/International – we are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity, and a drive to advance innovations that have a profound impact on patients. You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com.
Website:
www.kyowakirin.com
Representative:
Nicole Lesterick, Oncology Account Manager, Kyowa Kirin, Inc., 135 US-202, Bedminster, NJ 07921
Social Media
LinkedIn: Kyowa Kirin, Inc.- U.S.
Twitter: @KyowaKirin_US
YouTube: Kyowa Kirin North
America
Menarini Stemline
About Us
Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Our dedicated team of scientists, specialists, researchers, and developers are committed to providing transformational oncology treatments to those who need it, with the ultimate goal of improving the lives of those impacted by cancer.
Website:
https://stemline.com
Representative:
Angela Csaszar, Director, Oncology Access
[email protected]
Social Media:
Linked In: https://www.linkedin.com/company/menarinistemline/
X: https://x.com/stemline?s=21
Sanofi
Website:
www.sanofioncology.com
Representatives:
Nanette Rutherford, Field Reimbursement Manager
724-708-6495
[email protected]
Social Media:
Facebook: https://www.facebook.com/Sanofi/
LinkedIn: https://www.linkedin.com/company/sanofi
Twitter: https://twitter.com/SanofiUS
Instagram: https://www.instagram.com/sanofi/
CareASSIST Patient Support Information:
www.sanofioncology.com
Representatives:
Nanette Rutherford, Field Reimbursement Manager
724-708-6495
[email protected]
Social Media:
Facebook: https://www.facebook.com/Sanofi/
LinkedIn: https://www.linkedin.com/company/sanofi
Twitter: https://twitter.com/SanofiUS
Instagram: https://www.instagram.com/sanofi/
CareASSIST Patient Support Information:
Sumitomo
About Sumitomo
Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), Canada (Sumitomo Pharma Canada, Inc.) and Europe (Sumitomo Pharma Switzerland GmbH) focused on addressing patient needs in oncology, urology, women's health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website https://www.us.sumitomo-pharma.com or follow us on LinkedIn.
Website:
www.us.sumitomo-pharma.com
Representatives:
Dan Smith
814-322-5050
Dan.smith@us.sumitomo-pharma.com
Social Media:LinkedIn https://www.linkedin.com/company/sumitomo-pharma-america
X - @SumtiomoPharma
Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.), Canada (Sumitomo Pharma Canada, Inc.) and Europe (Sumitomo Pharma Switzerland GmbH) focused on addressing patient needs in oncology, urology, women's health, rare diseases, psychiatry & neurology, and cell & gene therapies. With several marketed products in the U.S., Canada, and Europe, a diverse pipeline of early- to late-stage assets, we aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. For more information on SMPA, visit our website https://www.us.sumitomo-pharma.com or follow us on LinkedIn.
Website:
www.us.sumitomo-pharma.com
Representatives:
Dan Smith
814-322-5050
Dan.smith@us.sumitomo-pharma.com
Social Media:LinkedIn https://www.linkedin.com/company/sumitomo-pharma-america
X - @SumtiomoPharma
